Pfizer has entered into agreements with the U.S. government to supply 10 million courses of Paxlovid, an oral drug it is developing to treat COVOD-19. The deal is worth $5.29 billion. The company has already submitted an application to the FDA for approval for emergency use of the drug. Delivery will take place only if Paxlovid is approved by the regulator.